Name change reflects transition towards potential commercial organization in 2027

Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026

enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (NASDAQ:ENGN, "enGene" or the "Company"))), a clinical-stage, non-viral genetic medicines company, is pleased to announce that it will change its corporate name to "enGene Therapeutics Inc." effective April 8, 2026. The Company elected to change its corporate name to reflect the near-term transition to a commercial organization with the potential approval of detalimogene voraplasmid in 2027. enGene's ongoing LEGEND trial is investigating detalimogene across several cohorts of high-risk non-muscle invasive bladder cancer (NMIBC), including a pivotal cohort in BCG-unresponsive NMIBC with carcinoma in situ (CIS).